{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:10:39Z","timestamp":1795039839137,"version":"4.10.2"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Synapse loss is linked to cognitive symptoms in Alzheimer\u2019s Disease (AD) and Cerebrospinal fluid (CSF) synaptic biomarkers may clarify disease heterogeneity and disease mechanisms for progression beyond amyloid (A\u03b2) and tau pathologies, potentially revealing new drug targets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used a mass-spectrometry panel of 17 synaptic biomarkers including neuronal pentraxins (NPTXs) linked to glutamatergic signaling, and 14-3-3 proteins linked to tau-pathology and synaptic plasticity. Synapse markers were evaluated in two independent cohorts: Dementia Disease Initiation (DDI) (<jats:italic>n<\/jats:italic>\u2009=\u2009346) and Amsterdam Dementia Cohort (n\u2009=\u2009<jats:italic>397<\/jats:italic>), both with cognitive assessments up to 10 years. We used linear regression to compare synapse marker differences between CSF-determined A\u03b2\u2009+\u2009cognitively normal (CN) and Mild Cognitive Impairment (MCI) groups, with or without CSF tau pathology (Tau+\/-), relative to CN A\u03b2-\/Tau- controls; and associations between synapse markers and medial temporal lobe (MTL) MRI volumetrics in the DDI cohort and with verbal memory in both cohorts. A funneling procedure identified proteins related to A\u03b2\/Tau pathology and memory impairment in both cohorts, which were used to evaluate relations to A\u03b2\/Tau biological progression in the DDI cohort and memory decline in both cohorts. Finally, we explored genetic pathways associated with these synaptic proteins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In both cohorts, most markers were elevated in A\u03b2+\/Tau\u2009+\u2009cases compared to controls, particularly 14-3-3\u03b6\/\u03b4. Several proteins were reduced in A\u03b2+\/Tau- cases, especially NPTX-2, while 14-3-3\u03b6\/\u03b4 remained elevated. However, the increase in e.g. 14-3-3\u03b6\/\u03b4 and reduction in e.g. NPTX2 were more pronounced in patients with MCI than CN cases regardless of tau-pathology, corresponding to verbal memory impairment and MTL atrophy. Elevated baseline 14-3-3\u03b6\/\u03b4 and rab GDP Dissociation Inhibitor Alpha (GDI-1) associated with future progression from A\u03b2+\/Tau- to A\u03b2+\/Tau+. Significant associations (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were found between 14-3-3 protein genes (<jats:italic>YWHAZ<\/jats:italic>, <jats:italic>YWHAE<\/jats:italic>) and pathways linked to AD, including the p38 MAPK, IGF, PIK3\/AKT and between <jats:italic>GDI1<\/jats:italic> and p38 MAPK upstream pathway (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) all connected to synaptic plasticity. Correspondingly, a robust 14-3-3\u03b6\/\u03b4 association with future memory decline was observed in both cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Reduced markers for excitatory signaling in A\u03b2+\/Tau- and increased synaptic plasticity markers in A\u03b2+\/Tau\u2009+\u2009cases suggest differential but linked processes underlying disease progression and resilience in the groups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13024-025-00899-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:09:28Z","timestamp":1760360968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer\u2019s disease genetic pathways"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-9578","authenticated-orcid":false,"given":"Bj\u00f8rn-Eivind","family":"Kirsebom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Vromen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Mikael","family":"Arnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atle","family":"Bj\u00f8rnerud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Br\u00e5then","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril Rolfseng","family":"Gr\u00f8ntvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Jarholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Nordengen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"P\u00e5lhaugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Selnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikias","family":"Siafarikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild Eide","family":"Skogseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Tecel\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Waterloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Tijms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"3","key":"899_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi M. Forecasting the global burden of Alzheimer\u00b4s disease. Alzheimer\u00b4s Dement. 2007;3(3):186\u201391.","journal-title":"Alzheimer\u00b4s Dement"},{"issue":"6","key":"899_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"899_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"899_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3233\/JAD-150137","volume":"48","author":"P Mistridis","year":"2015","unstructured":"Mistridis P, Krumm S, Monsch AU, Berres M, Taylor KI. The 12 years preceding mild cognitive impairment due to Alzheimer\u2019s disease: the Temporal emergence of cognitive decline. J Alzheimer\u2019s Disease: JAD. 2015;48(4):1095\u2013107.","journal-title":"J Alzheimer\u2019s Disease: JAD"},{"issue":"1","key":"899_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JAD-221274","volume":"94","author":"JA Jarholm","year":"2023","unstructured":"Jarholm JA, Bjornerud A, Dalaker TO, Akhavi MS, Kirsebom BE, Palhaugen L, et al. Medial Temporal lobe atrophy in predementia Alzheimer\u2019s disease: A longitudinal Multi-Site study comparing staging and A\/T\/N in a clinical research cohort. J Alzheimers Dis. 2023;94(1):259\u201379.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"899_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","volume":"118","author":"T Arendt","year":"2009","unstructured":"Arendt T. Synaptic degeneration in Alzheimer\u2019s disease. Acta Neuropathol. 2009;118(1):167\u201379.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"899_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"11","key":"899_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151\u201362.","journal-title":"JAMA"},{"issue":"4","key":"899_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385\u201393.","journal-title":"JAMA"},{"issue":"6","key":"899_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"key":"899_CR11","doi-asserted-by":"publisher","unstructured":"Jack Jr. CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s & Dementia. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859","DOI":"10.1002\/alz.13859"},{"issue":"1","key":"899_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13195-020-00742-y","volume":"13","author":"RS O\u2019Dell","year":"2021","unstructured":"O\u2019Dell RS, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, et al. Association of Abeta deposition and regional synaptic density in early Alzheimer\u2019s disease: a PET imaging study with [(11)C]UCB-J. Alzheimers Res Ther. 2021;13(1):11.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"899_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ana.26725","volume":"94","author":"A Soldan","year":"2023","unstructured":"Soldan A, Oh S, Ryu T, Pettigrew C, Zhu Y, Moghekar A, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment. Ann Neurol. 2023;94(4):620\u201331.","journal-title":"Ann Neurol"},{"issue":"s1","key":"899_CR14","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3233\/JAD-240610","volume":"100","author":"FH Duits","year":"2024","unstructured":"Duits FH, Nilsson J, Zetterberg H, Blennow K, van der Flier WM, Teunissen CE, et al. Serial cerebrospinal fluid sampling reveals trajectories of potential synaptic biomarkers in early stages of Alzheimer\u2019s disease. J Alzheimer\u2019s Disease: JAD. 2024;100(s1):S103\u201314.","journal-title":"J Alzheimer\u2019s Disease: JAD"},{"issue":"5054","key":"899_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Sci (New York NY). 1992;256(5054):184\u20135.","journal-title":"Sci (New York NY)"},{"issue":"12","key":"899_CR16","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/archneurol.2011.183","volume":"68","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68(12):1526\u201335.","journal-title":"Arch Neurol"},{"key":"899_CR17","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA118.001290","volume-title":"Changes in synaptic proteins precede neurodegeneration markers in preclinical alzheimer\u2019s disease cerebrospinal fluid","author":"A Lleo","year":"2019","unstructured":"Lleo A, Nunez-Llaves R, Alcolea D, Chiva C, Balateu-Panos D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Molecular & cellular proteomics: MCP; 2019."},{"issue":"1","key":"899_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-022-00521-3","volume":"17","author":"PJ Visser","year":"2022","unstructured":"Visser PJ, Reus LM, Gobom J, Jansen I, Dicks E, van der Lee SJ, et al. Cerebrospinal fluid Tau levels are associated with abnormal neuronal plasticity markers in Alzheimer\u2019s disease. Mol Neurodegeneration. 2022;17(1):27.","journal-title":"Mol Neurodegeneration"},{"issue":"1","key":"899_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12974-023-02973-w","volume":"20","author":"K Nordengen","year":"2023","unstructured":"Nordengen K, Kirsebom BE, Richter G, Palhaugen L, Gisladottir B, Siafarikas N, et al. Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer\u2019s disease. J Neuroinflammation. 2023;20(1):298.","journal-title":"J Neuroinflammation"},{"key":"899_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fncir.2013.00017","volume":"7","author":"JV Perederiy","year":"2013","unstructured":"Perederiy JV, Westbrook GL. Structural plasticity in the dentate gyrus- revisiting a classic injury model. Front Neural Circuits. 2013;7:17.","journal-title":"Front Neural Circuits"},{"key":"899_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fncel.2019.00575","volume":"13","author":"G Chapman","year":"2019","unstructured":"Chapman G, Shanmugalingam U, Smith PD. The role of neuronal pentraxin 2 (NP2) in regulating glutamatergic signaling and neuropathology. Front Cell Neurosci. 2019;13:575.","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"899_CR22","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/s41380-024-02473-0","volume":"29","author":"C Soares","year":"2024","unstructured":"Soares C, Da Ros LU, Machado LS, Rocha A, Lazzarotto G, Carello-Collar G, et al. The glutamatergic system in Alzheimer\u2019s disease: a systematic review with meta-analysis. Mol Psychiatry. 2024;29(7):2261\u201373.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"899_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40659-024-00537-7","volume":"57","author":"R Alfaro-Ruiz","year":"2024","unstructured":"Alfaro-Ruiz R, Martin-Belmonte A, Aguado C, Moreno-Martinez AE, Fukazawa Y, Lujan R. Selective disruption of synaptic NMDA receptors of the hippocampal trisynaptic circuit in Abeta pathology. Biol Res. 2024;57(1):56.","journal-title":"Biol Res"},{"issue":"14","key":"899_CR24","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","volume":"16","author":"T G\u00f3mez-Isla","year":"1996","unstructured":"G\u00f3mez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer\u2019s disease. J Neuroscience: Official J Soc Neurosci. 1996;16(14):4491\u2013500.","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"key":"899_CR25","doi-asserted-by":"crossref","unstructured":"Cummings DM, Benway TA, Ho H, Tedoldi A, Freitas MMF, Shahab L, et al. Neuronal and peripheral pentraxins modify glutamate release and may interact in blood-brain barrier failure. Cerebral Cortex (New York, NY: 1991). 2017;27(6):3437-48.","DOI":"10.1093\/cercor\/bhx046"},{"issue":"5","key":"899_CR26","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/alz.12809","volume":"19","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2023;19(5):1775\u201384.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"899_CR27","doi-asserted-by":"publisher","first-page":"8407609","DOI":"10.1155\/2018\/8407609","volume":"2018","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhou Y. 14-3-3 proteins in glutamatergic synapses. Neural Plast. 2018;2018:8407609.","journal-title":"Neural Plast"},{"key":"899_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms22179207","volume":"22","author":"J Sinsky","year":"2021","unstructured":"Sinsky J, Pichlerova K, Hanes J. Tau protein interaction partners and their roles in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci. 2021;22:17.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"899_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12031-019-01325-9","volume":"68","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen X, Yao Z, Shi Y, Xiong J, Zhou J, et al. 14-3-3\/Tau interaction and Tau amyloidogenesis. J Mol Neuroscience: MN. 2019;68(4):620\u201330.","journal-title":"J Mol Neuroscience: MN"},{"issue":"4","key":"899_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-004-0885-4","volume":"108","author":"T Umahara","year":"2004","unstructured":"Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T, Ikeda K, et al. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer\u2019s disease. Acta Neuropathol. 2004;108(4):279\u201386.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"899_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12017-018-8479-9","volume":"20","author":"S Veleri","year":"2018","unstructured":"Veleri S, Punnakkal P, Dunbar GL, Maiti P. Molecular insights into the roles of Rab proteins in intracellular dynamics and neurodegenerative diseases. Neuromolecular Med. 2018;20(1):18\u201336.","journal-title":"Neuromolecular Med"},{"key":"899_CR32","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319.","journal-title":"Biomark Insights"},{"key":"899_CR33","doi-asserted-by":"crossref","unstructured":"Nilsson J, Gobom J, Sjodin S, Brinkmalm G, Ashton NJ, Svensson J, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease. Alzheimer\u2019s Dement (Amsterdam Netherlands). 2021;13(1):e12179.","DOI":"10.1002\/dad2.12179"},{"key":"899_CR34","doi-asserted-by":"crossref","unstructured":"Brinkmalm G, Sjodin S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, et al. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer\u2019s disease. Proteom Clin Appl. 2018;12(1).","DOI":"10.1002\/prca.201700131"},{"key":"899_CR35","doi-asserted-by":"publisher","first-page":"941927","DOI":"10.3389\/fnagi.2022.941927","volume":"14","author":"Y Lu","year":"2022","unstructured":"Lu Y. Early increase of cerebrospinal fluid 14-3-3zeta protein in the Alzheimer\u2019s disease continuum. Front Aging Neurosci. 2022;14:941927.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"899_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-170231","volume":"60","author":"T Fladby","year":"2017","unstructured":"Fladby T, Palhaugen L, Selnes P, Waterloo K, Brathen G, Hessen E, et al. Detecting At-Risk Alzheimer\u2019s disease cases. J Alzheimers Dis. 2017;60(1):97\u2013105.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"899_CR37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):844\u201352.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"899_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2011;7(3):270\u20139.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"2","key":"899_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jalz.2007.08.005","volume":"4","author":"GG Fillenbaum","year":"2008","unstructured":"Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, et al. Consortium to Establish a registry for Alzheimer\u2019s disease (CERAD): the first Twenty years. Alzheimers Dement. 2008;4(2):96\u2013109.","journal-title":"Alzheimers Dement"},{"key":"899_CR40","doi-asserted-by":"publisher","unstructured":"Kirsebom BE, Espenes R, Hessen E, Waterloo K, Johnsen SH, Gundersen E, et al. Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years. Clin Neuropsychol. 2019:1\u201313.Neuropsychologist, 33(sup1), 27\u201339. https:\/\/doi.org\/10.1080\/13854046.2019.1574902","DOI":"10.1080\/13854046.2019.1574902"},{"key":"899_CR41","volume-title":"The Halstead-Reitan neuropsychological test battery: therapy and clinical assessment","author":"R Reitan","year":"1985","unstructured":"Reitan R, Wolfson D. The Halstead-Reitan neuropsychological test battery: therapy and clinical assessment. Tucson, AZ: Neuropsychological; 1985."},{"issue":"sup1","key":"899_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/13854046.2020.1829068","volume":"34","author":"J Espenes","year":"2020","unstructured":"Espenes J, Hessen E, Eliassen IV, Waterloo K, Eckerstr\u00f6m M, Sando SB, et al. Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years. Clin Neuropsychol. 2020;34(sup1):110\u201326.","journal-title":"Clin Neuropsychol"},{"key":"899_CR43","volume-title":"Multilingual aphasia examination","author":"AL Benton","year":"1989","unstructured":"Benton AL. Hamsher Kd. Multilingual aphasia examination. Iowa City: AJA Associates; 1989."},{"key":"899_CR44","doi-asserted-by":"publisher","unstructured":"Lorentzen IM, Espenes J, Hessen E, Waterloo K, Br\u00e5then G, Tim\u00f3n S, et al. Regression-based norms for the FAS phonemic fluency test for ages 40\u201384 based on a Norwegian sample. Applied Neuropsychology: Adult. 2023;30(2):159\u201368. https:\/\/doi.org\/10.1080\/23279095.2021.1918128","DOI":"10.1080\/23279095.2021.1918128"},{"key":"899_CR45","volume-title":"The visual object and space perception battery","author":"EK Warrington","year":"1991","unstructured":"Warrington EK, James M. The visual object and space perception battery. Bury St Edmunds, England: Thames Valley Test Company; 1991."},{"issue":"8","key":"899_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1037\/neu0000698","volume":"34","author":"IV Eliassen","year":"2020","unstructured":"Eliassen IV, Fladby T, Kirsebom BE, Waterloo K, Eckerstr\u00f6m M, Wallin A, et al. Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer\u2019s pathology and progression to dementia. Neuropsychology. 2020;34(8):851\u201361.","journal-title":"Neuropsychology"},{"issue":"3","key":"899_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimer\u2019s Disease: JAD. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimer\u2019s Disease: JAD"},{"key":"899_CR48","doi-asserted-by":"crossref","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINDS-ARDRA work group under the auspices of health and human services task force on Alzheimer\u2019s disease. Neurology. 1984;34PBS Record: 210:939\u2009\u2013\u200944.","DOI":"10.1212\/WNL.34.7.939"},{"issue":"3","key":"899_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"899_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138.","journal-title":"Arch Neurol"},{"issue":"1","key":"899_CR51","doi-asserted-by":"publisher","first-page":"20375","DOI":"10.1038\/s41598-021-99794-9","volume":"11","author":"N Siafarikas","year":"2021","unstructured":"Siafarikas N, Kirsebom BE, Srivastava DP, Eriksson CM, Auning E, Hessen E, et al. Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Sci Rep. 2021;11(1):20375.","journal-title":"Sci Rep"},{"key":"899_CR52","first-page":"111","volume-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Volume 8. Amsterdam, Netherlands: Alzheimer\u2019s & dementia; 2017. pp. 111\u201326."},{"issue":"22","key":"899_CR53","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322.","journal-title":"Neurology"},{"issue":"3","key":"899_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid Amyloid-beta 1\u201342 analysis results. Clin Chem. 2018;64(3):576\u201385.","journal-title":"Clin Chem"},{"issue":"2","key":"899_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1\u201342), total Tau, and phosphorylated Tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56(2):248\u201353.","journal-title":"Clin Chem"},{"issue":"4","key":"899_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2018;14(4):535\u201362.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"1","key":"899_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-024-00755-3","volume":"19","author":"S Lehmann","year":"2024","unstructured":"Lehmann S, Schraen-Maschke S, Bu\u00e9e L, Vidal J-S, Delaby C, Hirtz C, et al. Clarifying the association of CSF A\u03b2, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease. Mol Neurodegeneration. 2024;19(1):66.","journal-title":"Mol Neurodegeneration"},{"issue":"1","key":"899_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with Tau and amyloid pathology. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2019;15(1):55\u201364.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"899_CR59","doi-asserted-by":"crossref","unstructured":"Plubell DL, Wilmarth PA, Zhao Y, Fenton AM, Minnier J, Reddy AP, et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol Cell Proteomics. 2017;16(5):873\u2009\u2013\u200990.","DOI":"10.1074\/mcp.M116.065524"},{"issue":"1","key":"899_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, Vromen EM, Mjaavatten O, Holstege H, Reus LM, van der Lee S, et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4(1):33\u201347.","journal-title":"Nat Aging"},{"issue":"6","key":"899_CR61","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.conb.2011.10.021","volume":"21","author":"M Gallagher","year":"2011","unstructured":"Gallagher M, Koh MT. Episodic memory on the path to Alzheimer\u2019s disease. Curr Opin Neurobiol. 2011;21(6):929\u201334.","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"899_CR62","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1017\/S1355617705050344","volume":"11","author":"W Van der Elst","year":"2005","unstructured":"Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J. Rey\u2019s verbal learning test: normative data for 1855 healthy participants aged 24\u201381 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychological Society: JINS. 2005;11(3):290\u2013302.","journal-title":"J Int Neuropsychological Society: JINS"},{"key":"899_CR63","volume-title":"R: A Language and environment for statistical computing","author":"RC Team","year":"2022","unstructured":"Team RC. R: A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022."},{"issue":"4","key":"899_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"899_CR65","unstructured":"Fortin J-P. neuroCombat: Harmonization of multi-site imaging data with ComBat. 2024."},{"key":"899_CR66","doi-asserted-by":"publisher","unstructured":"Wickham H, L\u00fcdecke D. ggpubr: \u2018ggplot2\u2019 based publication ready plots. 2022;3. https:\/\/doi.org\/10.21105\/joss.00772. Available from: https:\/\/CRAN.R-project.org\/package=ggpubrhttps:\/\/ggplot2.tidyverse.org","DOI":"10.21105\/joss.00772"},{"key":"899_CR67","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00772","author":"H Wickham","year":"2016","unstructured":"Wickham H, L\u2019fcdecke D. ggplot2: elegant graphics for data analysis ggeffects: tidy data frames of marginal effects from regression models. New York: Springer-Verlag. 2016. https:\/\/doi.org\/10.21105\/joss.00772. p.","journal-title":"New York: Springer-Verlag"},{"key":"899_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2019.00445","volume":"10","author":"R Huang","year":"2019","unstructured":"Huang R, Grishagin I, Wang Y, Zhao T, Greene J, Obenauer JC, et al. The NCATS BioPlanet - An integrated platform for exploring the universe of cellular signaling pathways for Toxicology, systems Biology, and chemical genomics. Front Pharmacol. 2019;10:445.","journal-title":"Front Pharmacol"},{"key":"899_CR69","doi-asserted-by":"crossref","unstructured":"Hugon J, Paquet C. The PKR\/P38\/RIPK1 signaling pathway as a therapeutic target in Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(6).","DOI":"10.3390\/ijms22063136"},{"issue":"3","key":"899_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","volume":"23","author":"B Kim","year":"2012","unstructured":"Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23(3):133\u201341.","journal-title":"Trends Endocrinol Metab"},{"key":"899_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ebiom.2019.03.051","volume":"42","author":"SA Hari Dass","year":"2019","unstructured":"Hari Dass SA, McCracken K, Pokhvisneva I, Chen LM, Garg E, Nguyen TTT, et al. A biologically-informed polygenic score identifies endophenotypes and clinical conditions associated with the insulin receptor function on specific brain regions. EBioMedicine. 2019;42:188\u2013202.","journal-title":"EBioMedicine"},{"issue":"3","key":"899_CR72","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s12640-019-0003-y","volume":"35","author":"SN Rai","year":"2019","unstructured":"Rai SN, Dilnashin H, Birla H, Singh SS, Zahra W, Rathore AS, et al. The role of PI3K\/Akt and ERK in neurodegenerative disorders. Neurotox Res. 2019;35(3):775\u201395.","journal-title":"Neurotox Res"},{"issue":"1","key":"899_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-019-0469-0","volume":"11","author":"L Magno","year":"2019","unstructured":"Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, et al. Alzheimer\u2019s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11(1):16.","journal-title":"Alzheimers Res Ther"},{"issue":"689","key":"899_CR74","doi-asserted-by":"publisher","first-page":"eadf0141","DOI":"10.1126\/scitranslmed.adf0141","volume":"15","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wade SD, Graykowski D, Xiao MF, Zhao B, Giannini LAA, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med. 2023;15(689):eadf0141.","journal-title":"Sci Transl Med"},{"key":"899_CR75","doi-asserted-by":"publisher","first-page":"1286536","DOI":"10.3389\/fmolb.2024.1286536","volume":"11","author":"G Abdi","year":"2024","unstructured":"Abdi G, Jain M, Patil N, Upadhyay B, Vyas N, Dwivedi M, et al. 14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer\u2019s disease. Front Mol Biosci. 2024;11:1286536.","journal-title":"Front Mol Biosci"},{"key":"899_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ijms21165624","volume":"21","author":"C Falcicchia","year":"2020","unstructured":"Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Involvement of p38 MAPK in synaptic function and dysfunction. Int J Mol Sci. 2020;21:16.","journal-title":"Int J Mol Sci"},{"key":"899_CR77","doi-asserted-by":"publisher","first-page":"635636","DOI":"10.3389\/fcell.2021.635636","volume":"9","author":"E Beamer","year":"2021","unstructured":"Beamer E, Correa SAL. The p38(MAPK)-MK2 signaling axis as a critical link between inflammation and synaptic transmission. Front Cell Dev Biol. 2021;9:635636.","journal-title":"Front Cell Dev Biol"},{"key":"899_CR78","doi-asserted-by":"crossref","unstructured":"Detka J, Plachtij N, Strzelec M, Manik A, Salat K. p38alpha mitogen-activated protein kinase-an emerging drug target for the treatment of Alzheimer\u2019s disease. Molecules. 2024;29(18).","DOI":"10.3390\/molecules29184354"},{"issue":"1\u20132","key":"899_CR79","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/21541248.2017.1397833","volume":"9","author":"MJ Banworth","year":"2018","unstructured":"Banworth MJ, Li G. Consequences of Rab GTPase dysfunction in genetic or acquired human diseases. Small GTPases. 2018;9(1\u20132):158\u201381.","journal-title":"Small GTPases"},{"issue":"1","key":"899_CR80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-023-44374-w","volume":"15","author":"N Franzmeier","year":"2024","unstructured":"Franzmeier N, Dehsarvi A, Steward A, Biel D, Dewenter A, Roemer SN, et al. Elevated CSF GAP-43 is associated with accelerated Tau accumulation and spread in Alzheimer\u2019s disease. Nat Commun. 2024;15(1):202.","journal-title":"Nat Commun"},{"issue":"Pt 7","key":"899_CR81","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1093\/brain\/aws120","volume":"135","author":"A Andreyeva","year":"2012","unstructured":"Andreyeva A, Nieweg K, Horstmann K, Klapper S, Muller-Schiffmann A, Korth C, et al. C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-beta. Brain. 2012;135(Pt 7):2140\u201354.","journal-title":"Brain"},{"issue":"5","key":"899_CR82","doi-asserted-by":"publisher","first-page":"fcac244","DOI":"10.1093\/braincomms\/fcac244","volume":"4","author":"BE Kirsebom","year":"2022","unstructured":"Kirsebom BE, Richter G, Nordengen K, Aarsland D, Brathen G, Tijms BM, et al. Stable cerebrospinal fluid neurogranin and beta-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer\u2019s disease patients. Brain Commun. 2022;4(5):fcac244.","journal-title":"Brain Commun"},{"issue":"4","key":"899_CR83","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57(4):1041\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"899_CR84","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuroscience.2007.06.037","volume":"149","author":"L Dissing-Olesen","year":"2007","unstructured":"Dissing-Olesen L, Ladeby R, Nielsen HH, Toft-Hansen H, Dalmau I, Finsen B. Axonal lesion-induced microglial proliferation and microglial cluster formation in the mouse. Neuroscience. 2007;149(1):112\u201322.","journal-title":"Neuroscience"},{"issue":"3","key":"899_CR85","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20131685","volume":"211","author":"K Yamada","year":"2014","unstructured":"Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. Neuronal activity regulates extracellular Tau in vivo. J Exp Med. 2014;211(3):387\u201393.","journal-title":"J Exp Med"},{"issue":"6","key":"899_CR86","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913\u201322.","journal-title":"Neuron"},{"issue":"1","key":"899_CR87","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41398-022-02024-7","volume":"12","author":"H Targa Dias Anastacio","year":"2022","unstructured":"Targa Dias Anastacio H, Matosin N, Ooi L. Neuronal hyperexcitability in Alzheimer\u2019s disease: what are the drivers behind this aberrant phenotype? Translational Psychiatry. 2022;12(1):257.","journal-title":"Translational Psychiatry"},{"issue":"12","key":"899_CR88","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/brain\/awaa325","volume":"143","author":"BM Tijms","year":"2020","unstructured":"Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, et al. Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776\u201392.","journal-title":"Brain"},{"issue":"1","key":"899_CR89","doi-asserted-by":"publisher","first-page":"19399","DOI":"10.1038\/s41598-025-04319-3","volume":"15","author":"EM Planalp","year":"2025","unstructured":"Planalp EM, Langhough RE, Jonaitis EM, Van Hulle CA, Wilson RE, Kollmorgen G, et al. Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer\u2019s disease cohort. Sci Rep. 2025;15(1):19399.","journal-title":"Sci Rep"},{"issue":"7","key":"899_CR90","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain. 2024;147(7):2414\u201327.","journal-title":"Brain"},{"issue":"1","key":"899_CR91","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12864-021-07502-8","volume":"22","author":"PD Karp","year":"2021","unstructured":"Karp PD, Midford PE, Caspi R, Khodursky A. Pathway size matters: the influence of pathway granularity on over-representation (enrichment analysis) statistics. BMC Genomics. 2021;22(1):191.","journal-title":"BMC Genomics"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00899-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:16:17Z","timestamp":1760368577000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00899-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00899-w","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The DDI study was approved by the Regional Committees for Medical and Health Research Ethics in Norway and conducted in line with the guidelines provided by the Helsinki declaration, and the Norwegian Health and Research act. All participants volunteered and gave written informed consent before participating in the study. All patients in the ADC study gave written informed consent, was in line with the guidelines provided by the Helsinki declaration, was approved by the ethics committee of the Amsterdam UMC (location VUmc), the Biobank Research Ethics Committee of the Amsterdam UMC (location VUmc).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the contents of this manuscript and have provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BEK has served as a consultant for Biogen and on an advisory board for Eisai and Eli Lilly. TF has served as a consultant and at the advisory boards for Biogen, Novo Nordisk, Eli Lilly, Roche and Eisai. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). PS has served as a consultant for Roche. RES has served on an advisory board for Eisai and as local PI on GSK 219867. DA has received research support and\/or honoraria from, Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura and Cognetivity. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}